GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Charles River Laboratories International Inc (NYSE:CRL) » Definitions » Accounts Payable & Accrued Expense

Charles River Laboratories International (Charles River Laboratories International) Accounts Payable & Accrued Expense : $321 Mil (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Charles River Laboratories International Accounts Payable & Accrued Expense?

Charles River Laboratories International's quarterly accounts payable & accrued expense increased from Sep. 2023 ($379 Mil) to Dec. 2023 ($397 Mil) but then declined from Dec. 2023 ($397 Mil) to Mar. 2024 ($321 Mil).

Charles River Laboratories International's annual accounts payable & accrued expense declined from Dec. 2021 ($427 Mil) to Dec. 2022 ($426 Mil) and declined from Dec. 2022 ($426 Mil) to Dec. 2023 ($397 Mil).


Charles River Laboratories International Accounts Payable & Accrued Expense Historical Data

The historical data trend for Charles River Laboratories International's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Charles River Laboratories International Accounts Payable & Accrued Expense Chart

Charles River Laboratories International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 276.68 297.18 426.93 425.67 396.76

Charles River Laboratories International Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 379.79 405.72 379.28 396.76 320.57

Charles River Laboratories International Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.


Charles River Laboratories International (Charles River Laboratories International) Business Description

Traded in Other Exchanges
Address
251 Ballardvale Street, Wilmington, MA, USA, 01887
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Executives
Victoria L Creamer officer: EVP & Chief People Officer 164 PINE HILL ROAD, NEW FAIRFIELD CT 06812
Joseph W Laplume officer: EVP, Corp Strategy & Develop 251 BALLARDVALE STREET, WILMINGTON MA 01887
Birgit Girshick officer: Corporate Executive VP 251 BALLARDVALE STREET, WILMINGTON MA 01887
James C Foster director, officer: President and CEO 251 BALLARDVALE ST, WILMINGTON MA 01887
Richard F Wallman director HONEYWELL, 101 COLUMBIA ROAD, MORRISTOWN NJ 07962
William D Barbo officer: Corporate Executive VP & CCO 251 BALLARDVALE STREET, WILMINGTON MA 01887
Michael Gunnar Knell officer: CSVP&Chief Accounting Officer BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
George Massaro director
Shannon M Parisotto officer: CEVP, Disc & Safety Assessment 251 BALLARDVALE ST, WILMINGTON MA 01887
Flavia Pease officer: Corporate Executive VP 251 BALLARDVALE STREET, WILMINGTON MA 01887
David Ross Smith officer: Corporate Executive VP & CFO 251 BALLARDVALE STREET, WILMINGTON MA 01887
Deborah Turner Kochevar director 251 BALLARDVALE STREET, WILMINGTON MA 01887
Milne George M Jr director
Stephen D Chubb director C/O MATRITECH INC, 330 NEVADA STREET, NEWTON MA 02460
George Llado director 251 BALLARDVALE STREET, WILMINGTON MA 01887